Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Phase 3positiveGedatolisibAlpelisibFulvestrantPositive
AI Analysis
Summary
Celcuity announced that gedatolisib combination regimens doubled the likelihood of survival without disease progression or death versus alpelisib plus fulvestrant in the PIK3CA mutant cohort of the pivotal Phase 3 VIKTORIA-1 trial for HR+/HER2- advanced breast cancer.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Gedatolisib combination regimens doubled the likelihood of survival without disease progression or death compared to alpelisib plus fulvestrant in PIK3CA mutant cohort
Importance:8/10
Sentiment:
0.85
Phase 3 trialbreast cancergedatolisibpositive dataVIKTORIA-1HR+/HER2- breast cancer
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 2, 2026 8:07 PM